---
title: "PharmaCyte Biotech Inc. Delays Annual Financial Report Due to Extended Preparation Needs"
description: "PharmaCyte Biotech Inc. has delayed its Annual Report on Form 10-K for the fiscal year ending April 30, 2025, originally due on July 29, 2025. The company requires additional time to prepare and revie"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250662773.md"
published_at: "2025-07-29T21:27:01.000Z"
---

# PharmaCyte Biotech Inc. Delays Annual Financial Report Due to Extended Preparation Needs

> PharmaCyte Biotech Inc. has delayed its Annual Report on Form 10-K for the fiscal year ending April 30, 2025, originally due on July 29, 2025. The company requires additional time to prepare and review its financial statements to ensure proper disclosure. The report is expected to be filed no later than 15 days after the original due date.

PharmaCyte Biotech Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended April 30, 2025. The company cited the need for additional time to prepare and review its financial statements to ensure adequate disclosure. The report, originally due on July 29, 2025, is expected to be filed no later than 15 calendar days following the prescribed due date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-005492), on July 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PMCB.US - PharmaCyte Biotech](https://longbridge.com/en/quote/PMCB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pharmala Biotech 任命 Lennie Ryer 加入董事会，同时 Malik Slassi 辞去职务 | Pharmala Biotech Holdings Inc. 宣布其董事会发生变更，Dr. Malik Slassi 辞职，Lennie Ryer, CPA, CA 被任命为新董事会成员。此次更新是公司持续治理调整的一部分 | [Link](https://longbridge.com/en/news/275514575.md) |
| BB Biotech AG 提议每股派发 2.25 瑞士法郎的股息 | BB Biotech AG 提议为 2025 财年每股派发 2.25 瑞士法郎的股息，较去年每股 1.80 瑞士法郎的派息有所增加。该提案将在 2026 年 3 月 19 日的年度股东大会上提交批准 | [Link](https://longbridge.com/en/news/273469604.md) |
| PharmaCyte Biotech 的首席执行官 Joshua Silverman 收购了普通股 | PharmaCyte Biotech 首席执行官 Joshua Silverman 已经购买了该公司的普通股。完整的文件可以通过提供的链接查看。此消息由 Public Technologies 生成，仅供信息参考，不应被视为财务、投资或法律 | [Link](https://longbridge.com/en/news/271847803.md) |
| PharmaCyte 的顶级内部人士悄然大幅增持股份 | PharmaCyte Biotech (PMCB) 在 2026 年 1 月 7 日经历了显著的内部买入，首席执行官 Joshua Silverman 购买了 100,000 股，花费 80,000 美元，董事 Jonathan Schec | [Link](https://longbridge.com/en/news/271873123.md) |
| MediPharm Labs 任命 Greg Hunter 为临时 CEO | MediPharm Labs Corp. 已任命 Greg Hunter 为临时首席执行官，任命将于 2026 年 1 月 23 日生效，此前首席执行官 David Pidduck 辞职，但他将继续留任董事会。Hunter 目前担任首席财务 | [Link](https://longbridge.com/en/news/272974985.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.